IP Library Patent Application 16103680
Patent Application
App. No. 16/103,680

SONODYNAMIC THERAPY

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/103,680
Abstract

The present disclosure provides methods for treating diseased cells in a subject using sonodynamic therapy (SDT), comprising: administering to the subject a sonosensitizer composition comprising IRDye® 700DX, wherein the sonosensitizer composition associates with the diseased cell; and thereafter applying an ultrasonic wave to the diseased cell.

Claims (22)

1 . A method for treating a diseased cell in a subject using sonodynamic therapy, said method comprising:

administering to the subject a sonosensitizer composition comprising IRDye® 700DX, wherein the sonosensitizer associates with the diseased cell; and

applying an ultrasonic wave to the diseased cell.

2 . The method of claim 1 , wherein said diseased cell is a cancer cell.

3 . The method of claim 2 , wherein said cancer cell is a cell of a solid tumor.

4 . The method of claim 3 , wherein said solid tumor is a member selected from the group consisting of lung, breast, bladder, ovarian, pancreatic, skin, esophagus, stomach, liver, colon and prostate cancer.

5 . The method of claim 1 , wherein said sonosensitizer composition comprises a carrier moiety.

6 . The method of claim 5 , wherein said carrier moiety is a virus-like particle.

7 . The method of claim 6 , wherein said virus-like particle comprises a L1 caspid protein, a L2 caspid protein or a combination thereof

8 . The method of claim 5 , wherein said carrier moiety is a nanotube.

9 . The method of claim 1 , wherein said sonosensitizer composition comprises a targeting agent.

10 . The method of claim 9 , wherein said targeting agent is an antibody.

11 . The method of claim 1 , wherein said administration comprises systemic administration to the subject, local administration to a tumor, or administration to a surgical site.

12 . The method of claim 1 , wherein said ultrasonic wave is applied at a frequency of about 0.1 MHz to about 30 MHz.

13 . The method of claim 12 , wherein said ultrasonic wave is applied at a frequency of about 1.0 MHz to about 5.0 MHz.

14 . The method of claim 12 , wherein said ultrasonic wave is applied at a frequency of about 1.0 MHz to about 2.0 MHz.

15 . The method of claim 1 , wherein said ultrasonic wave is applied at a power density of about 0.01 W/cm 2 to about 12 W/cm 2 .

16 . The method of claim 15 , wherein said ultrasonic wave is applied at a power density of about 1.0 W/cm 2 to about 6 W/cm 2 .

17 . The method of claim 15 , wherein said ultrasonic wave is applied at a power density of about 1.2 W/cm 2 to about 3.8 W/cm 2 .

18 . The method of claim 1 , wherein the ultrasonic wave is generated from an ultrasonic transducer applied locally.

19 . The method of claim 1 , wherein the ultrasonic transducer is appended to an endoscope.

20 . A kit, the kit comprising a sonosensitizer composition comprising IRDye® 700DX.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 11, 2021
From: LI-COR, INC.
To: RAKUTEN MEDICAL, INC.
Reel/Frame 055238/0885 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 19, 2018
From: WANG, HAN-WEI; MIDDENDORF, LYLE R.
To: LI-COR, INC.
Reel/Frame 047233/0363 →